ReviewClinical pharmacology and therapeutics2020
Management of Osteoarthritis During the COVID-19 Pandemic.
Review in Clinical pharmacology and therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Effects of Exercise-Based Telerehabilitation for Knee Osteoarthritis: A Systematic Review and a Study Protocol.Bioengineering (Basel, Switzerland) · 2026Review
- Introducing a specified on-line multimodal prehabilitation approach for total knee replacement surgery candidates using data from the COVID-19 pandemic: An exploratory field-based, pre-post, mixed methods implementation pilot study.Journal of evaluation in clinical practice · 2025Article
- Pharmacological Pain Treatment in Older Persons.Drugs & aging · 2024Review
- Increasing Burden of Osteoarthritis in China: Trends and Projections from the Global Burden of Disease Study 2019.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Key personal insights and changing needs of osteoarthritis patients: an international quantitative survey analysis.Reumatologia · 2024Article
- Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.Journal of community hospital internal medicine perspectives · 2024Review
- Challenges with patient management of osteoarthritis during the COVID-19 pandemic: review.Annals of medicine and surgery (2012) · 2023Article
- Causal influences of osteoarthritis on COVID-19: a Mendelian randomization study.Frontiers in medicine · 2023Article
- Review
- COVID-19 and rheumatic diseases: A mini-review.Frontiers in medicine · 2022Review
- MicroRNA-186 ameliorates Knee osteoarthritis via regulation of P2X7-mediated Cathepsin-K/Runx2/ADAMTS5 signalling axis in articular chondrocytes.Saudi journal of biological sciences · 2021Article
- Clinical Activities, Contaminations of Surgeons and Cooperation with Health Authorities in 14 Orthopedic Departments in North Italy during the Most Acute Phase of Covid-19 Pandemic.International journal of environmental research and public health · 2021Article
- Comparison of two ASC-derived therapeutics in an in vitro OA model: secretome versus extracellular vesicles.Stem cell research & therapy · 2020Article
- Rheumatologists' practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt.Rheumatology international · 2020Article
- COVID-19: not a contraindication for surgery in patients with proximal femur fragility fractures.Journal of orthopaedic surgery and research · 2020Article
- Prediction of COVID-19 Patients at High Risk of Progression to Severe Disease.Frontiers in public health · 2020Article
- Effectiveness of tele-rehabilitation in patients with knee osteoarthritis: A randomized controlled trial.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
The pandemic spread of the new coronavirus disease 2019 (COVID-19) infection in China first, and all over the world at present, has become a global health emergency due to the rapidly increasing number of affected patients. Currently, a clear relationship between COVID-19 infection incidence and/or complications due to chronic or occasional treatments for other pathologies is still not clear, albeit the COVID-19 pandemic may condition the treatment strategy of complex disorders, such as osteoarthritis (OA). Importantly, OA is the most common age-related joint disease, affecting more than 80% of people older than the age of 55, an age burden also shared with the highest severity in COVID-19 patients. OA patients often show a large array of concomitant pathologies, such as diabetes, inflammation, and cardiovascular diseases that are again shared with COVID-19 patients and may therefore increase complications. Moreover, different OA treatments, such as NSAIDs, paracetamol, corticosteroids, opioids, or other molecules have a wide array of iatrogenic effects, potentially increasing COVID-19 secondary infection incidence or complications. In this review we critically analyze the evidence on either negative or positive effects of drugs commonly used to manage OA in this particular scenario. This would provide orthopedic surgeons in particular, and physicians, pharmacologists, and clinicians in general, a comprehensive description about the safety of the current pharmacological approaches and a decision-making tool to treat their OA patients as the coronavirus pandemic continues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.